Backed by Sean Harp­er and Beth Sei­den­berg, an LA biotech scores a mas­sive $250M crossover ahead of 2022 IPO

When Ace­lyrin closed its Se­ries A late last year, it was met with lit­tle fan­fare. The biotech had on­ly two em­ploy­ees, the for­mer R&D chief and CBO of Hori­zon Ther­a­peu­tics, and didn’t even dis­close the size of the raise. West­lake Vil­lage BioPart­ners, an LA-based VC firm and lead in­vestor, proved the most note­wor­thy as­pect of the an­nounce­ment, hav­ing spawned from ex-Am­gen R&D head Sean Harp­er and ex-Klein­er Perkins life sci­ences di­rec­tor Beth Sei­den­berg.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER